Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Elesclomol> ?p ?o. }
Showing items 1 to 61 of
61
with 100 items per page.
- Elesclomol abstract "Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year.In a small, randomized phase II study, elesclomol was shown to significantly increase progression-free survival in people with metastatic melanoma when given in addition to paclitaxel (Taxol).".
- Elesclomol atcPrefix "none".
- Elesclomol casNumber "488832-69-5".
- Elesclomol fdaUniiCode "6UK191M53P".
- Elesclomol iupacName "N′1,N′3-dimethyl-N′1,N′3- bis(phenylcarbonothioyl)propanedihydrazide".
- Elesclomol pubchem "300471".
- Elesclomol thumbnail Elesclomol.svg?width=300.
- Elesclomol wikiPageID "20362616".
- Elesclomol wikiPageRevisionID "604254823".
- Elesclomol alt "Skeletal formula".
- Elesclomol alt "Space-filling model".
- Elesclomol atcPrefix "none".
- Elesclomol c "19".
- Elesclomol casNumber "488832".
- Elesclomol chembl "1972860".
- Elesclomol chemspiderid "265501".
- Elesclomol h "20".
- Elesclomol hasPhotoCollection Elesclomol.
- Elesclomol image "Elesclomol-3D-spacefill.png".
- Elesclomol iupacName "N′1,N′3-dimethyl-N′1,N′3- bispropanedihydrazide".
- Elesclomol molecularWeight "400.518".
- Elesclomol n "4".
- Elesclomol o "2".
- Elesclomol pubchem "300471".
- Elesclomol s "2".
- Elesclomol stdinchi "1".
- Elesclomol stdinchikey "BKJIXTWSNXCKJH-UHFFFAOYSA-N".
- Elesclomol unii "6".
- Elesclomol verifiedfields "changed".
- Elesclomol verifiedrevid "446146469".
- Elesclomol watchedfields "changed".
- Elesclomol width "250".
- Elesclomol subject Category:Chemotherapeutic_adjuvants.
- Elesclomol subject Category:Hydrazides.
- Elesclomol subject Category:Orphan_drugs.
- Elesclomol type Addition102679415.
- Elesclomol type Additive102679788.
- Elesclomol type Adjuvant102680947.
- Elesclomol type Agent114778436.
- Elesclomol type CausalAgent100007347.
- Elesclomol type ChemotherapeuticAdjuvants.
- Elesclomol type Component103081021.
- Elesclomol type Drug103247620.
- Elesclomol type Matter100020827.
- Elesclomol type Object100002684.
- Elesclomol type OrphanDrugs.
- Elesclomol type Part103892891.
- Elesclomol type PhysicalEntity100001930.
- Elesclomol type Substance100020090.
- Elesclomol type Drug.
- Elesclomol type DrugProduct.
- Elesclomol type FunctionalSubstance.
- Elesclomol comment "Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns.".
- Elesclomol label "Elesclomol".
- Elesclomol sameAs m.04zxdbn.
- Elesclomol sameAs Q5359460.
- Elesclomol sameAs Q5359460.
- Elesclomol sameAs Elesclomol.
- Elesclomol wasDerivedFrom Elesclomol?oldid=604254823.
- Elesclomol depiction Elesclomol.svg.
- Elesclomol isPrimaryTopicOf Elesclomol.